July 27, 2021
Your specialty pharmacy is underperforming. What do you do now?
When you launched your biopharmaceutical product for a rare condition several years ago, you believed…
Read More
May 18, 2021
hae day :-): Optimizing Care for Patients with Hereditary Angioedema
Now celebrating its 10th anniversary, hae day :-) is an awareness campaign that unites the…
Read More
April 27, 2021
Patient Experience Week: Addressing the Challenges of Patients Living with a Rare Disorder
Patient Experience Week (PX Week), April 26-30, 2021, is an annual event to celebrate the…
Read More
December 8, 2020
The Proven Model for Improving Clinical Trial Results During the Pandemic
The pharmaceutical industry has not escaped the impact of the COVID-19 crisis. Every phase of…
Read More
November 23, 2020
How to Build an Integrated Service Model for Rare and Orphan Drugs
Six Questions You Should Ask a Consultant Many drug manufacturers and healthcare consultants attempt to…
Read More
October 16, 2020
9 Steps to Improving Patient Access to Rare and Orphan Drugs
A conversation on eHealth Radio Recently, I had the privilege of a thought-provoking conversation on…
Read More
September 22, 2020
How to Stay Focused on Rare and Orphan Disorders in the Time of COVID
4 Critical Success Factors for Manufacturers Before I became president and CEO of Optime Care,…
Read More
August 20, 2020
Product First Means Patients Left Behind
A tale of too many patients. My family has a long history of alpha-1 antitrypsin…
Read More
July 13, 2020
Scale vs. Service? Your rare drug demands both.
When developing a drug commercialization strategy, there’s a misconception that patient service and program scalability are mutually exclusive. The prevailing…
Read More
June 18, 2020
Revealing 5 hidden truths about using a hub-and-spoke model for rare and orphan drugs
The hub-and-spoke approach has become a standard of drug commercialization. Having a network of patient…
Read More
